Bioasis Technologies Inc. Announces Stock Option Grants
Bioasis Technologies Inc. Announces Stock Option Grants
NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 platform for delivering therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, today announced that it has granted stock options to acquire a total of 2,011,000 common shares effective August 8, 2022 at a price of $0.13 per share to directors and officers of the Company and an investor relations consultant. All of the options expire five years from the date of the grant and are governed by the terms of the company's stock option plan. The options are being issued as part of annual remuneration.
康涅狄格州纽黑文，2022年8月8日(Global Newswire)--BiOasis Technologies Inc..(多伦多证券交易所股票代码：BTI；OTCQB：BIOAF)，(公司或生物绿洲)，一家多资产罕见和孤儿疾病生物制药公司，基于表皮生长因子和差异化、专有的xB开发临床阶段计划3在高度未得到满足的医疗需求地区提供跨越血脑屏障(BBB)的治疗药物和治疗中枢神经系统(CNS)疾病的平台, 今天宣布，已向公司董事和高级管理人员以及一名投资者关系顾问授予股票期权，从2022年8月8日起以每股0.13美元的价格收购总计2,011,000股普通股。所有期权自授予之日起五年到期，并受该公司股票期权计划的条款管辖。这些期权是作为年度薪酬的一部分发布的。
On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Executive Chair of the Board
代表BiOasis Technologies Inc.董事会。
Deborah Rathjen，博士，董事会执行主席
Follow on:
Facebook
Instagram
LinkedIn
Twitter
后续内容：
Facebook
Instagram
LinkedIn
推特
BTI-CRP
BTI-CRP
About Bioasis
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit .
关于BiOASIS
BiOasis Technologies Inc.是一家多资产罕见和孤儿疾病生物制药公司，开发基于表皮生长因子和xB的临床分期计划3™Platform是一项专利技术，用于通过血脑屏障提供治疗药物，并在高度未得到满足的医疗需求领域治疗中枢神经系统疾病。通过血脑屏障提供治疗药物代表着治疗神经疾病的最后前沿。BiOASIS的内部开发计划旨在为与大脑相关的疾病和障碍开发对症和疾病修改治疗。欲了解更多有关该公司的信息，请访问。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
多伦多证券交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任
Contacts:
Deborah Rathjen, Ph.D., Executive Chair of the Board and CEO
deborah@bioasis.us
203-533-7082
联系人：
黛博拉·拉特金博士，董事会执行主席兼首席执行官
邮箱：deborah@biasis.us
203-533-7082
Investor Contact:
Graeme Dick
Colwell Capital Corp.
graeme@colwellcapital.com
403-561-8989
投资者联系方式：
格雷姆·迪克
科尔韦尔资本公司
邮箱：graeme@colwell capal.com
403-561-8989
译文内容由第三方软件翻译。